Endocytosis in cancer and cancer therapy
Endocytosis is a complex process whereby cell surface proteins, lipids and fluid from the
extracellular environment are packaged, sorted and internalized into cells. Endocytosis is …
extracellular environment are packaged, sorted and internalized into cells. Endocytosis is …
ImmunoPET: concept, design, and applications
W Wei, ZT Rosenkrans, J Liu, G Huang, QY Luo… - Chemical …, 2020 - ACS Publications
Immuno-positron emission tomography (immunoPET) is a paradigm-shifting molecular
imaging modality combining the superior targeting specificity of monoclonal antibody (mAb) …
imaging modality combining the superior targeting specificity of monoclonal antibody (mAb) …
Trastuzumab mechanism of action; 20 years of research to unravel a dilemma
Simple Summary Overexpression of HER2 receptors have been identified in various types of
cancer including breast cancer and ovarian cancer. HER2 overexpression is generally …
cancer including breast cancer and ovarian cancer. HER2 overexpression is generally …
Circular RNA circCCDC9 acts as a miR-6792-3p sponge to suppress the progression of gastric cancer through regulating CAV1 expression
Z Luo, Z Rong, J Zhang, Z Zhu, Z Yu, T Li, Z Fu, Z Qiu… - Molecular cancer, 2020 - Springer
Background As a novel type of noncoding RNAs, covalently closed circular RNAs
(circRNAs) are ubiquitously expressed in eukaryotes. Emerging studies have related …
(circRNAs) are ubiquitously expressed in eukaryotes. Emerging studies have related …
Resistance to trastuzumab
S Vivekanandhan, KL Knutson - Cancers, 2022 - mdpi.com
Simple Summary Trastuzumab is a humanized antibody that has significantly improved the
management and treatment outcomes of patients with cancers that overexpress HER2 …
management and treatment outcomes of patients with cancers that overexpress HER2 …
Intraoperative evaluation of tumor margins using a TROP2 near-infrared imaging probe to enable human breast-conserving surgery
W Chen, Y Zhang, L Zhang, X Luo, X Yang… - Science Translational …, 2024 - science.org
Intraoperative surgical margin assessment remains a challenge during breast-conserving
surgery. Here, we report a combined strategy of immuno–positron emission tomography …
surgery. Here, we report a combined strategy of immuno–positron emission tomography …
Overcoming trastuzumab resistance in HER2‐positive breast cancer using combination therapy
A Derakhshani, Z Rezaei, H Safarpour… - Journal of cellular …, 2020 - Wiley Online Library
Human epidermal growth factor receptor 2 (HER2)‐positive breast cancer (BC) comprises
around 20–30% of all BC subtypes and is correlated with poor prognosis. For many years …
around 20–30% of all BC subtypes and is correlated with poor prognosis. For many years …
[HTML][HTML] A comprehensive review of HER2 in cancer biology and therapeutics
X Cheng - Genes, 2024 - mdpi.com
Human epidermal growth factor receptor 2 (HER2), a targetable transmembrane
glycoprotein receptor of the epidermal growth factor receptor (EGFR) family, plays a crucial …
glycoprotein receptor of the epidermal growth factor receptor (EGFR) family, plays a crucial …
Rise of antibody-drug conjugates: the present and future
M Shastry, A Gupta, S Chandarlapaty… - American Society of …, 2023 - ascopubs.org
Antibody-drug conjugates (ADCs) embody a simple, but elegant, vision for cancer therapy—
the delivery of a potent cytotoxic agent to tumor cells with minimal damage to normal cells …
the delivery of a potent cytotoxic agent to tumor cells with minimal damage to normal cells …
The efficacy of tucatinib-based therapeutic approaches for HER2-positive breast cancer
Overexpression of human epidermal growth factor receptor 2 (HER2) occurs in
approximately 15–20% of breast cancer cases. HER2 is a member of the epidermal growth …
approximately 15–20% of breast cancer cases. HER2 is a member of the epidermal growth …